Kahn Brothers Group Has Upped Glaxosmithkline (GSK) Position; Microsoft (MSFT) Share Value …

… 16/05/2018 – Regina Leader: Microsoft planning low-cost Surface tablet line to take on iPad; 10/04/2018 – C3 IoT and Microsoft Announce Strategic …

Microsoft Corporation (NASDAQ:MSFT) Logo

Bill & Melinda Gates Foundation Trust decreased its stake in Microsoft Corp (MSFT) by 50% based on its latest 2019Q1 regulatory filing with the SEC. Bill & Melinda Gates Foundation Trust sold 8.00M shares as the company’s stock rose 6.56% . The hedge fund held 8.00M shares of the prepackaged software company at the end of 2019Q1, valued at $943.52M, down from 16.00 million at the end of the previous reported quarter. Bill & Melinda Gates Foundation Trust who had been investing in Microsoft Corp for a number of months, seems to be less bullish one the $ market cap company. The stock increased 1.83% or $2.45 during the last trading session, reaching $136.13. About 25.03 million shares traded or 2.63% up from the average. Microsoft Corporation (NASDAQ:MSFT) has risen 29.33% since August 18, 2018 and is uptrending. It has outperformed by 29.33% the S&P500. Some Historical MSFT News: 14/03/2018 – Monaco Joins the Enterprise Ethereum Alliance; 30/05/2018 – Sabre Joins Forces with Microsoft to Reimagine the Business of Travel; 17/04/2018 – Tech firms, including Microsoft, Facebook, vow not to aid government cyber attacks; 27/03/2018 – Starr Companies Announces Agreement with SkyWatch for Aviation lnsureds; 19/03/2018 – White House chief of staff John Kelly has appointed former Microsoft and General Motors executive Chris Liddell to be his deputy in charge of policy; 16/05/2018 – Regina Leader: Microsoft planning low-cost Surface tablet line to take on iPad; 10/04/2018 – C3 IoT and Microsoft Announce Strategic Partnership to Accelerate AI in the Enterprise; 12/03/2018 – WANdisco Approved to Sell Data Platform in Microsoft Bundle; 29/05/2018 – Salesforce quarterly revenue rises 25.4 pct; 07/03/2018 – DocuSign picks banks for potential IPO in April

Kahn Brothers Group Inc increased its stake in Glaxosmithkline (GSK) by 1.24% based on its latest 2019Q1 regulatory filing with the SEC. Kahn Brothers Group Inc bought 15,610 shares as the company’s stock rose 2.15% . The hedge fund held 1.28 million shares of the major pharmaceuticals company at the end of 2019Q1, valued at $53.35 billion, up from 1.26M at the end of the previous reported quarter. Kahn Brothers Group Inc who had been investing in Glaxosmithkline for a number of months, seems to be bullish on the $99.56 billion market cap company. The stock increased 0.58% or $0.23 during the last trading session, reaching $40.19. About 1.37M shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 0.49% since August 18, 2018 and is uptrending. It has outperformed by 0.49% the S&P500. Some Historical GSK News: 29/05/2018 – GlaxoSmithKline Files Application to Japanese Regulator For Trelegy Ellipta; 24/05/2018 – GSK May Look at Merger Options for Indian Unit -The Economic Times; 18/04/2018 – GSK IMPACT STUDY SHOWS BENEFITS OF TRELEGY ELLIPTA; 25/04/2018 – HPV Vaccine Market 2022 Demand, Key Players- Merck and Co., GlaxoSmithKline; 22/03/2018 – GSK’s pursuit of Pfizer consumer unit need not be a costly move; 11/04/2018 – Fitch Affirms Sr. Unsecured Instrument Rating at ‘A’ for Debt Issued by GlaxoSmithKline Capital PLC and GlaxoSmithKline Capital Inc; 18/04/2018 – GSK grabs Roche cancer expert to lead pharma pipeline deals; 25/04/2018 – GlaxoSmithKline 1Q Adjusted Op Pft GBP1.92B; 22/03/2018 – GSK advances in Pfizer consumer health auction as Reckitt quits; 27/03/2018 – Yahoo! Finance: Nestle, other food groups likely suitors for GSK’s Horlicks

More notable recent GlaxoSmithKline plc (NYSE:GSK) news were published by: Streetinsider.com which released: “GSK raises 2019 earnings expectations after standout quarter for Shingrix – StreetInsider.com” on July 24, 2019, also Bizjournals.com with their article: “GSK, Pfizer complete deal to combine consumer health brands – Philadelphia Business Journal” published on August 01, 2019, Finance.Yahoo.com published: “Kahn Brothers’ Top 6 Buys in the 2nd Quarter – Yahoo Finance” on August 06, 2019. More interesting news about GlaxoSmithKline plc (NYSE:GSK) were released by: Seekingalpha.com and their article: “Glaxo’s Shingrix conditionally OK’d in China – Seeking Alpha” published on May 22, 2019 as well as Seekingalpha.com‘s news article titled: “Glaxo launches late-stage development of RA med otilimab – Seeking Alpha” with publication date: July 03, 2019.

Kahn Brothers Group Inc, which manages about $640.04B US Long portfolio, decreased its stake in Exxon Mobile (NYSE:XOM) by 248 shares to 19,574 shares, valued at $1.58B in 2019Q1, according to the filing. It also reduced its holding in American Tel & Tel by 50 shares in the quarter, leaving it with 12,587 shares, and cut its stake in Seaboard Corp (NYSEMKT:SEB).

Investors sentiment decreased to 0.91 in Q1 2019. Its down 0.03, from 0.94 in 2018Q4. It dropped, as 64 investors sold MSFT shares while 922 reduced holdings. 159 funds opened positions while 742 raised stakes. 5.41 billion shares or 1.21% less from 5.48 billion shares in 2018Q4 were reported. Jensen Inv Mngmt Incorporated holds 6.06% in Microsoft Corporation (NASDAQ:MSFT) or 4.32 million shares. 1.00M are held by Hitchwood Cap Lp. Clough Capital Prtn LP holds 2.96% or 287,000 shares. Kepos Cap LP reported 23,500 shares. Nordea Inv Mgmt Ab reported 8.87 million shares. Bahl & Gaynor has 4.63% invested in Microsoft Corporation (NASDAQ:MSFT) for 4.28M shares. Weiss Multi has invested 0.33% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Telemus Cap Ltd accumulated 168,765 shares. Price T Rowe Associate Inc Md holds 3.36% of its portfolio in Microsoft Corporation (NASDAQ:MSFT) for 193.86M shares. Hs Management Prns Ltd Limited Liability Company owns 737,526 shares for 2.94% of their portfolio. Stone Ridge Asset Mgmt Ltd Liability accumulated 0.23% or 34,340 shares. New England Invest Retirement Gp Incorporated invested in 1,750 shares. New York-based Alkeon Mgmt Limited Liability Corporation has invested 1.33% in Microsoft Corporation (NASDAQ:MSFT). Pggm Invs owns 561,155 shares. 3G Capital Ltd Partnership stated it has 12.62% of its portfolio in Microsoft Corporation (NASDAQ:MSFT).

Microsoft Corporation (NASDAQ:MSFT) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Eulav Asset Management Lowered Proofpoint (PFPT) Holding; Sphera Funds Management LTD …

Crosslink Capital Inc owns 115,967 shares for 3.49% of their portfolio. Oak Ridge Limited Liability Corporation has invested 0.19% in Proofpoint, Inc.

Proofpoint, Inc. (NASDAQ:PFPT) Logo

Eulav Asset Management decreased Proofpoint Inc (PFPT) stake by 20.58% reported in 2019Q1 SEC filing. Eulav Asset Management sold 9,300 shares as Proofpoint Inc (PFPT)’s stock rose 2.33%. The Eulav Asset Management holds 35,900 shares with $4.38M value, down from 45,200 last quarter. Proofpoint Inc now has $6.57 billion valuation. The stock increased 2.06% or $2.37 during the last trading session, reaching $117.15. About 590,403 shares traded or 15.27% up from the average. Proofpoint, Inc. (NASDAQ:PFPT) has risen 11.35% since August 17, 2018 and is uptrending. It has outperformed by 11.35% the S&P500. Some Historical PFPT News: 21/05/2018 – Wombat Security Launches Second GDPR Training Module to Improve Employee Understanding of Secure Data Handling; 12/03/2018 Proofpoint Enterprise Archive 4.0 Reduces Time and Cost with Enhanced eDiscovery Visualizations, Mobile Support, and User Inter; 15/05/2018 – Whale Rock Capital Management Buys 2.1% Position in Proofpoint; 26/04/2018 – Proofpoint 1Q Adj EPS 30c; 26/04/2018 – PROOFPOINT INC SEES 2018 NON-GAAP NET INCOME $1.00 TO $1.09 PER SHARE; 29/05/2018 – Proofpoint Presenting at Cowen Conference Tomorrow; 02/05/2018 – Proofpoint Presenting at Cowen Conference May 30; 13/03/2018 – Malwarebytes could consider IPO in 12 months – CEO; 26/04/2018 – PROOFPOINT 1Q REV. $162.5M, EST. $152.0M; 26/04/2018 – Proofpoint Sees 2018 Adj EPS $1.00-Adj EPS $1.09

Sphera Funds Management Ltd increased Glaxosmithkline Plc (GSK) stake by 38.71% reported in 2019Q1 SEC filing. Sphera Funds Management Ltd acquired 120,000 shares as Glaxosmithkline Plc (GSK)’s stock rose 2.15%. The Sphera Funds Management Ltd holds 430,000 shares with $17.97M value, up from 310,000 last quarter. Glaxosmithkline Plc now has $99.56 billion valuation. The stock increased 0.58% or $0.23 during the last trading session, reaching $40.19. About 1.36 million shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 0.49% since August 17, 2018 and is uptrending. It has outperformed by 0.49% the S&P500. Some Historical GSK News: 29/05/2018 – GSK Submits Regulatory Application in Japan for Once-Daily Single lnhaler Triple Therapy FF/UMEC/Vl for Patients with COPD; 12/04/2018 – GLAXOSMITHKLINE PLC – ORCHARD TO ASSUME OBLIGATIONS ARISING FROM GSK’S 2010 COLLABORATION AGREEMENT WITH OSPEDALE SAN RAFFAELE, FONDAZIONE TELETHON; 23/05/2018 – MEDIA-GlaxoSmithKline exploring merger, share swap with potential buyers in India – Economic Times; 27/03/2018 – Investors cheer GSK-Novartis deal; 11/04/2018 – Fitch Affirms Sr. Unsecured Instrument Rating at ‘A’ for Debt Issued by GlaxoSmithKline Capital PLC and GlaxoSmithKline Capital Inc; 04/04/2018 – KYMERA THERAPEUTICS – GSK AND KYMERA ALSO AGREE TO COLLABORATE TO DISCOVER NOVEL E3 LIGASES; 23/03/2018 – SHINGRIX APPROVED IN EUROPE AND JAPAN; 28/03/2018 – GLAXOSMITHKLINE CONSUMER ACCEPTED MUKESH BUTANI RESIGNATION; 16/05/2018 – Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting; 18/04/2018 – GlaxoSmithKline: Study Results Published in New England Journal of Medicine

More notable recent GlaxoSmithKline plc (NYSE:GSK) news were published by: Bizjournals.com which released: “GSK’s new pharma president carries Merck, Pfizer experience – Triangle Business Journal” on August 13, 2019, also Bizjournals.com with their article: “GSK’s U.S. pharmaceutical unit will have a new leader in 2020 – Philadelphia Business Journal” published on August 12, 2019, Fool.com published: “Ionis Pharmaceuticals Looks to Partners to Pay the Bills – Motley Fool” on August 14, 2019. More interesting news about GlaxoSmithKline plc (NYSE:GSK) were released by: Bizjournals.com and their article: “GSK, Pfizer complete deal to combine consumer health brands – Philadelphia Business Journal” published on August 01, 2019 as well as Seekingalpha.com‘s news article titled: “Pfizer and Glaxo close OTC joint venture – Seeking Alpha” with publication date: August 01, 2019.

Sphera Funds Management Ltd decreased Arvinas Inc stake by 73,000 shares to 198,053 valued at $2.92 million in 2019Q1. It also reduced Minerva Neurosciences Inc (NASDAQ:NERV) stake by 140,000 shares and now owns 642,018 shares. Celgene Corp (NASDAQ:CELG) was reduced too.

Investors sentiment increased to 1.45 in Q1 2019. Its up 0.39, from 1.06 in 2018Q4. It increased, as 23 investors sold PFPT shares while 77 reduced holdings. 60 funds opened positions while 85 raised stakes. 50.53 million shares or 4.91% more from 48.17 million shares in 2018Q4 were reported. Crosslink Capital Inc owns 115,967 shares for 3.49% of their portfolio. Oak Ridge Limited Liability Corporation has invested 0.19% in Proofpoint, Inc. (NASDAQ:PFPT). Jacobs Levy Equity accumulated 35,487 shares. Landscape Capital Mgmt Limited Liability Corporation has invested 0.03% in Proofpoint, Inc. (NASDAQ:PFPT). Falcon Point Capital Ltd Limited Liability Company has 48,561 shares for 3.21% of their portfolio. Brown Advisory Inc accumulated 1,640 shares. Stone Ridge Asset Mngmt Limited Liability Corp holds 0.04% or 6,053 shares. Utah Retirement Sys owns 0.02% invested in Proofpoint, Inc. (NASDAQ:PFPT) for 9,449 shares. Teacher Retirement Of Texas reported 284,871 shares stake. Clough Capital Ptnrs Ltd Partnership has invested 0.67% in Proofpoint, Inc. (NASDAQ:PFPT). Trexquant Investment Limited Partnership has 0.1% invested in Proofpoint, Inc. (NASDAQ:PFPT). 488,213 are owned by Polar Cap Llp. New York-based Tiaa Cref Inv Lc has invested 0.09% in Proofpoint, Inc. (NASDAQ:PFPT). Federated Invsts Pa holds 2,034 shares. Millrace Asset Grp holds 4,359 shares.

More notable recent Proofpoint, Inc. (NASDAQ:PFPT) news were published by: Seekingalpha.com which released: “Proofpoint Q2 2019 Earnings Preview – Seeking Alpha” on July 24, 2019, also Nasdaq.com with their article: “Proofpoint (PFPT) to Post Q2 Earnings: What Lies Ahead? – Nasdaq” published on July 22, 2019, Seekingalpha.com published: “Proofpoint boosts full-year guidance after Q2 beat – Seeking Alpha” on July 25, 2019. More interesting news about Proofpoint, Inc. (NASDAQ:PFPT) were released by: Seekingalpha.com and their article: “Cowen expects cybersecurity earnings strength – Seeking Alpha” published on July 22, 2019 as well as Seekingalpha.com‘s news article titled: “Proofpoint: Invest In This People-Centric Cybersecurity Company – Seeking Alpha” with publication date: August 13, 2019.

Among 6 analysts covering Proofpoint Inc (NASDAQ:PFPT), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Proofpoint Inc has $145 highest and $9500 lowest target. $131.14’s average target is 11.94% above currents $117.15 stock price. Proofpoint Inc had 12 analyst reports since February 25, 2019 according to SRatingsIntel. Mizuho initiated the shares of PFPT in report on Tuesday, March 26 with “Hold” rating. The rating was maintained by Robert W. Baird on Monday, June 24 with “Buy”. KeyBanc Capital Markets maintained Proofpoint, Inc. (NASDAQ:PFPT) on Monday, February 25 with “Buy” rating. The stock has “Overweight” rating by Morgan Stanley on Tuesday, March 12. Needham maintained Proofpoint, Inc. (NASDAQ:PFPT) rating on Tuesday, March 12. Needham has “Buy” rating and $135 target. The stock of Proofpoint, Inc. (NASDAQ:PFPT) has “Outperform” rating given on Friday, April 12 by Wedbush.

Eulav Asset Management increased Progressive Corp Ohio (NYSE:PGR) stake by 10,700 shares to 54,700 valued at $3.98 million in 2019Q1. It also upped Iqvia Hldgs Inc stake by 16,900 shares and now owns 39,500 shares. Paycom Software Inc (NYSE:PAYC) was raised too.

Analysts await Proofpoint, Inc. (NASDAQ:PFPT) to report earnings on October, 24. They expect $-0.12 EPS, up 61.29% or $0.19 from last year’s $-0.31 per share. After $-0.27 actual EPS reported by Proofpoint, Inc. for the previous quarter, Wall Street now forecasts -55.56% EPS growth.

Proofpoint, Inc. (NASDAQ:PFPT) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

As Taiwan Semiconductor Mfg LTD (TSM) Shares Declined, Shareholder Natixis Decreased Its …

Some Historical TSM News: 15/05/2018 – Samsung in talks with ZTE, others to supply mobile processor chips – exec; 19/03/2018 – Brightwire: TSMC …

Pfizer Inc. (NYSE:PFE) Logo

Natixis decreased its stake in Taiwan Semiconductor Mfg Ltd (TSM) by 75.7% based on its latest 2019Q1 regulatory filing with the SEC. Natixis sold 20,798 shares as the company’s stock declined 2.72% . The institutional investor held 6,675 shares of the semiconductors company at the end of 2019Q1, valued at $269,000, down from 27,473 at the end of the previous reported quarter. Natixis who had been investing in Taiwan Semiconductor Mfg Ltd for a number of months, seems to be less bullish one the $210.08B market cap company. The stock increased 1.06% or $0.43 during the last trading session, reaching $40.86. About 7.23M shares traded. Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) has risen 3.75% since August 16, 2018 and is uptrending. It has outperformed by 3.75% the S&P500. Some Historical TSM News: 15/05/2018 – Samsung in talks with ZTE, others to supply mobile processor chips – exec; 19/03/2018 – Brightwire: TSMC rumored to run at full capacity through H2 after getting 12nm, 16nm process orders from MediaTek, Nvidia; 22/03/2018 – TAIWAN’S TSMC 2330.TW TSM.N SAYS ORDERS MACHINERY EQUIPMENT WORTH T$2.48 BLN; 28/03/2018 – TAIPEI — U.S. senior trade official met with Chairman Morris Chang of Taiwan Semiconductor Manufacturing Co., the world’s largest contract chipmaker, and other industry executives this week in Taiwan to foster greater collaboration, according to a source familiar with the matter and a local media report; 02/05/2018 – Taiwan Semiconductor Manufacturing 1Q Net Profit NT$89.78B; 22/03/2018 – Australian Gov: US Patent Issued to TAIWAN SEMICONDUCTOR MANUFACTURING on March 20 for “Source and drain process for FinFET”; 19/04/2018 – TSMC is the world’s largest semiconductor foundry company and manufactures chips for Apple and its component suppliers; 09/03/2018 – TSMC 2330.TW SAYS FEB SALES T$64.64 BLN (JAN T$79.74 BLN, 2017 DEC T$89.90 BLN); 09/03/2018 – Taiwan Semiconductor Manufacturing Feb Rev NT$64.64B; 16/03/2018 – TSMC 2330.TW SAYS IT ORDERS FACILITY AND CONSTRUCTION FOR T$301 MLN

Staley Capital Advisers Inc increased its stake in Pfizer Inc (PFE) by 0.8% based on its latest 2019Q1 regulatory filing with the SEC. Staley Capital Advisers Inc bought 8,542 shares as the company’s stock declined 4.73% . The institutional investor held 1.07M shares of the health care company at the end of 2019Q1, valued at $45.59M, up from 1.06M at the end of the previous reported quarter. Staley Capital Advisers Inc who had been investing in Pfizer Inc for a number of months, seems to be bullish on the $190.71 billion market cap company. The stock increased 0.70% or $0.24 during the last trading session, reaching $34.48. About 28.41M shares traded or 10.15% up from the average. Pfizer Inc. (NYSE:PFE) has risen 0.65% since August 16, 2018 and is uptrending. It has outperformed by 0.65% the S&P500. Some Historical PFE News: 21/04/2018 – DJ Pfizer Inc, Inst Holders, 1Q 2018 (PFE); 04/04/2018 – Pfizer: FDA Sets PDUFA Goal Date for Decision in September; 08/05/2018 – LUPIN SUBMITS NEW DRUG APPLICATION FOR ETANERCEPT BIOSIMILAR; 19/03/2018 – BIODURO SAYS AISF WAS DEVELOPED THROUGH A RESEARCH COLLABORATION WITH PFIZER INC; 23/03/2018 – GLAXOSMITHKLINE DID NOT PUT IN A FINAL BID FOR PFIZER’S CONSUMER HEALTHCARE UNIT – SOURCE FAMILIAR WITH SITUATION; 01/05/2018 – PFIZER 1Q ADJ EPS 77C, EST. 75C; REAFFIRMS 2018 GUIDANCE; 01/05/2018 – Pfizer 1Q Adj EPS 77c; 18/05/2018 – U.S. FDA SAYS THERE WAS NO CHANGE IN THE ADVERSE EVENT PROFILE OF KEYTRUDA OR TECENTRIQ; 29/05/2018 – Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New lndications; 05/03/2018 – PFIZER INC – LITTMAN WAS ALSO APPOINTED TO CORPORATE GOVERNANCE AND SCIENCE AND TECHNOLOGY COMMITTEES OF PFIZER’S BOARD

More notable recent Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) news were published by: Seekingalpha.com which released: “Wall Street Breakfast: Hopes Rise For More Fed Easing – Seeking Alpha” on July 19, 2019, also Fool.com with their article: “Is Taiwan Semiconductor a Buy? – Motley Fool” published on January 27, 2019, Fool.com published: “Intel Gives Chip Stocks Their Third Boost in a Week – Motley Fool” on August 01, 2019. More interesting news about Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) were released by: Finance.Yahoo.com and their article: “StockBeat – Semis Swoon as Huawei Gets Caught Up in US-China Crossfire Again – Yahoo Finance” published on August 09, 2019 as well as Seekingalpha.com‘s news article titled: “Chip analyst warns of Taiwan threat – Seeking Alpha” with publication date: August 13, 2019.

Natixis, which manages about $15.89B US Long portfolio, upped its stake in Lowes Cos Inc (NYSE:LOW) by 129,976 shares to 271,854 shares, valued at $29.46M in 2019Q1, according to the filing. It also increased its holding in Host Hotels & Resorts Inc (NYSE:HST) by 962,410 shares in the quarter, for a total of 1.02 million shares, and has risen its stake in Illumina Inc (NASDAQ:ILMN).

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “I’m Lowering My Fair Value Estimate For Pfizer – Seeking Alpha” on August 06, 2019, also Finance.Yahoo.com with their article: “Were Hedge Funds Right About Souring On Pfizer Inc. (PFE)? – Yahoo Finance” published on June 01, 2019, 247Wallst.com published: “Pfizer Once Again the Most Shorted Dow Stock – 24/7 Wall St.” on August 12, 2019. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer Q1 2019 Earnings Preview – Seeking Alpha” published on April 29, 2019 as well as Benzinga.com‘s news article titled: “‘Fast Money Halftime Report’ Traders Share Their Thoughts On Square, Boeing, And More – Benzinga” with publication date: August 01, 2019.

Investors sentiment increased to 0.76 in Q1 2019. Its up 0.02, from 0.74 in 2018Q4. It improved, as 66 investors sold PFE shares while 763 reduced holdings. 125 funds opened positions while 501 raised stakes. 3.88 billion shares or 4.26% less from 4.05 billion shares in 2018Q4 were reported. 61,198 are owned by Kwmg Ltd Co. Independent has invested 0.46% of its portfolio in Pfizer Inc. (NYSE:PFE). Burns J W New York holds 0.92% of its portfolio in Pfizer Inc. (NYSE:PFE) for 88,983 shares. Cadence Capital Limited Liability Corporation holds 146,416 shares or 0.56% of its portfolio. Private Wealth Prns Lc accumulated 450,308 shares. Guardian Invest Mngmt holds 59,297 shares or 2.18% of its portfolio. Eagle Asset Management Inc holds 1.94M shares or 0.44% of its portfolio. Stelac Advisory Ser Ltd Liability has 0.09% invested in Pfizer Inc. (NYSE:PFE). Robeco Institutional Asset Mgmt Bv invested 1.15% in Pfizer Inc. (NYSE:PFE). Hgk Asset Mngmt stated it has 0.19% in Pfizer Inc. (NYSE:PFE). D Scott Neal, a Kentucky-based fund reported 10,907 shares. Kings Point Capital Management holds 188,941 shares or 1.59% of its portfolio. Chemical Bancorporation holds 1.07% or 222,389 shares. Waddell Reed Finance accumulated 0.91% or 8.65M shares. Amer Economic Planning Group Adv holds 0.28% or 20,801 shares in its portfolio.

Staley Capital Advisers Inc, which manages about $1.31 billion and $1.35 billion US Long portfolio, decreased its stake in Intel Corp (NASDAQ:INTC) by 46,308 shares to 523,031 shares, valued at $28.09 million in 2019Q1, according to the filing. It also reduced its holding in Apple Inc (NASDAQ:AAPL) by 12,196 shares in the quarter, leaving it with 42,074 shares, and cut its stake in Ishares Short Maturity Bond.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Kahn Brothers Group Lifted Position in Glaxosmithkline (GSK); As Intel Com (INTC) Share Value …

Some Historical INTC News: 17/05/2018 – Intel Corporation’s (INTC) CEO Brian Krzanich Hosts 2018 Stockholders’ Meeting (Transcript); 09/03/2018 …

GlaxoSmithKline plc (NYSE:GSK) Logo

Kahn Brothers Group Inc increased its stake in Glaxosmithkline (GSK) by 1.24% based on its latest 2019Q1 regulatory filing with the SEC. Kahn Brothers Group Inc bought 15,610 shares as the company’s stock rose 2.15% . The hedge fund held 1.28 million shares of the major pharmaceuticals company at the end of 2019Q1, valued at $53.35 billion, up from 1.26M at the end of the previous reported quarter. Kahn Brothers Group Inc who had been investing in Glaxosmithkline for a number of months, seems to be bullish on the $101.26B market cap company. The stock increased 0.50% or $0.2 during the last trading session, reaching $40.51. About 3.12M shares traded or 33.52% up from the average. GlaxoSmithKline plc (NYSE:GSK) has risen 0.49% since August 7, 2018 and is uptrending. It has outperformed by 0.49% the S&P500. Some Historical GSK News: 11/04/2018 – Fitch Affirms GlaxoSmithKline’s Long-Term Issuer Default Rating at ‘A’; 06/03/2018 – GSK: Study Met Two Primary Endpoints Demonstrating Vaccine Efficacy; 09/05/2018 – GLAXOSMITHKLINE CFO TO RETIRE; 26/04/2018 – InSysBio, LLC Announces Extension of Collaboration With GSK on Quantitative Systems Pharmacology Modeling in Asthma; 27/03/2018 – S&PGRBulletin:GlaxoSmithKline To Buy Novartis Healthcare Stake; 19/04/2018 – GLAXOSMITHKLINE PLC GSK.L – TO FULLY UNDERSTAND IMPLICATIONS OF ALL-CAUSE MORTALITY OBSERVATION, OFF-TREATMENT DATA ALSO NEED TO BE CONSIDERED. WORK IS ONGOING TO INVESTIGATE THIS FURTHER AND WILL BE; 25/04/2018 – GlaxoSmithKline 1Q Adjusted Op Pft GBP1.92B; 27/03/2018 – GLAXOSMITHKLINE – CONSUMER HEALTHCARE BUSINESS TO CONTINUE TO INVEST IN GROWTH OPPORTUNITIES FOR OTC, ORAL HEALTH BRANDS, SUCH AS SENSODYNE AND ENO; 08/03/2018 – GSK and Innoviva Announce Positive EU Approval for Labelling Update to Relvar Ellipta in Patients With Asthma; 22/03/2018 – ? GSK leads race to […]

North Star Investment Management Corp increased its stake in Intel Corp Com (INTC) by 9.95% based on its latest 2019Q1 regulatory filing with the SEC. North Star Investment Management Corp bought 16,000 shares as the company’s stock declined 0.41% . The institutional investor held 176,842 shares of the semiconductors company at the end of 2019Q1, valued at $9.50 million, up from 160,842 at the end of the previous reported quarter. North Star Investment Management Corp who had been investing in Intel Corp Com for a number of months, seems to be bullish on the $214.55 billion market cap company. The stock decreased 0.49% or $0.23 during the last trading session, reaching $46.73. About 26.76M shares traded or 12.92% up from the average. Intel Corporation (NASDAQ:INTC) has risen 6.00% since August 7, 2018 and is uptrending. It has outperformed by 6.00% the S&P500. Some Historical INTC News: 17/05/2018 – Intel Corporation’s (INTC) CEO Brian Krzanich Hosts 2018 Stockholders’ Meeting (Transcript); 09/03/2018 – Intel Considers Acquisition Alternatives Including Possible Bid For; 09/03/2018 – Glancy Prongay & Murray LLP Reminds Investors of the March 12, 2018 Deadline in the Class Action Lawsuit Against Intel Corporation; 22/03/2018 – Sen. King: In Intel Hearing, King Emphasizes Severity of Threats to Election Security; 26/04/2018 – INTEL CORP INTC.O FY2018 SHR VIEW $3.57, REV VIEW $65.15 BLN — THOMSON REUTERS l/B/E/S; 17/04/2018 – ICON PACT W/INTEL ALLOWING INTEGRATION OF PHARMA ANALYTICS; 07/03/2018 – Hitachi High-Technologies Corporation Receives Intel’s Preferred Quality Supplier Award; 07/03/2018 – KLA-Tencor Receives Intel’s Preferred Quality Supplier Award; 27/04/2018 – House Intel Dems: Intel Committee Ranking Member Schiff Statement on Release of Majority’s Russia Report; 09/05/2018 – ♫ Reuters Insider – Flight path for U.S. drones without Amazon, DJI

North Star Investment Management Corp, which manages about $856.87M US Long portfolio, decreased its stake in Gannett Co Inc Com by 139,581 shares to 256,208 shares, valued at $2.70 million in 2019Q1, according to the filing. It also reduced its holding in Rocky Shoes & Boots Inc (NASDAQ:RCKY) by 36,449 shares in the quarter, leaving it with 254,520 shares, and cut its stake in Ishares S&P 500 Index (IVV).

Investors sentiment decreased to 0.86 in Q1 2019. Its down 0.14, from 1 in 2018Q4. It worsened, as 61 investors sold INTC shares while 733 reduced holdings. 139 funds opened positions while 541 raised stakes. 2.84 billion shares or 4.15% less from 2.96 billion shares in 2018Q4 were reported. Virginia Retirement Et Al has 1.18% invested in Intel Corporation (NASDAQ:INTC) for 1.86M shares. Fin Counselors has invested 1.18% in Intel Corporation (NASDAQ:INTC). 10 reported 290,342 shares or 3.35% of all its holdings. Moreover, Cleararc Cap has 1.1% invested in Intel Corporation (NASDAQ:INTC). Glaxis Management Lc, Florida-based fund reported 10,000 shares. Bernzott Cap holds 1.51% or 231,604 shares. Paradigm Fincl owns 2.1% invested in Intel Corporation (NASDAQ:INTC) for 103,267 shares. Mairs & Power has 392,312 shares for 0.26% of their portfolio. James Inv reported 2.06% of its portfolio in Intel Corporation (NASDAQ:INTC). Citigroup stated it has 2.43 million shares. Cornerstone Advsrs Incorporated accumulated 12,350 shares. Riverhead Management Ltd Liability Co has invested 0.72% of its portfolio in Intel Corporation (NASDAQ:INTC). First Republic Inv Mgmt holds 2.78 million shares. Hallmark Capital Mgmt reported 0.5% in Intel Corporation (NASDAQ:INTC). Alexandria Lc reported 197,144 shares.

More notable recent Intel Corporation (NASDAQ:INTC) news were published by: Nasdaq.com which released: “Dow Movers: INTC, GS – Nasdaq” on July 16, 2019, also 247Wallst.com with their article: “President Trump’s Huawei Pivot Could Be Huge for 3 Top Semiconductor Companies – 24/7 Wall St.” published on July 16, 2019, Nasdaq.com published: “Intel (INTC) Outpaces Stock Market Gains: What You Should Know – Nasdaq” on July 15, 2019. More interesting news about Intel Corporation (NASDAQ:INTC) were released by: Nasdaq.com and their article: “After-Hours Earnings Report for July 25, 2019 : AMZN, GOOG, GOOGL, INTC, SBUX, SYK, AFL, FISV, RSG, FTV, VRSN, EIX – Nasdaq” published on July 25, 2019 as well as Nasdaq.com‘s news article titled: “Notable Monday Option Activity: PZZA, VAC, INTC – Nasdaq” with publication date: August 05, 2019.

Kahn Brothers Group Inc, which manages about $640.04 billion US Long portfolio, decreased its stake in Citigroup by 26,466 shares to 920,627 shares, valued at $57.28 billion in 2019Q1, according to the filing. It also reduced its holding in Nam Tai Ppty (NYSE:NTP) by 22,621 shares in the quarter, leaving it with 1.88 million shares, and cut its stake in Blackberry (NASDAQ:BBRY).

Intel Corporation (NASDAQ:INTC) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Lantz Financial LLC Sells 6176 Shares of GlaxoSmithKline plc (NYSE:GSK)

Millennium Management LLC increased its stake in GlaxoSmithKline by 612.0% during the 4th quarter. Millennium Management LLC now owns …

GlaxoSmithKline logoLantz Financial LLC trimmed its holdings in GlaxoSmithKline plc (NYSE:GSK) by 41.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,831 shares of the pharmaceutical company’s stock after selling 6,176 shares during the quarter. Lantz Financial LLC’s holdings in GlaxoSmithKline were worth $361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of GSK. Norges Bank bought a new position in shares of GlaxoSmithKline in the 4th quarter worth about $17,275,000. Deutsche Bank AG increased its stake in GlaxoSmithKline by 221.0% during the 4th quarter. Deutsche Bank AG now owns 529,309 shares of the pharmaceutical company’s stock valued at $20,222,000 after purchasing an additional 364,431 shares in the last quarter. Millennium Management LLC increased its stake in GlaxoSmithKline by 612.0% during the 4th quarter. Millennium Management LLC now owns 365,325 shares of the pharmaceutical company’s stock valued at $13,959,000 after purchasing an additional 314,016 shares in the last quarter. Foundry Partners LLC bought a new stake in GlaxoSmithKline during the 1st quarter valued at about $6,917,000. Finally, CIBC Asset Management Inc increased its stake in GlaxoSmithKline by 184.2% during the 1st quarter. CIBC Asset Management Inc now owns 232,295 shares of the pharmaceutical company’s stock valued at $9,683,000 after purchasing an additional 150,545 shares in the last quarter. Institutional investors own 11.26% of the company’s stock.

Shares of NYSE GSK opened at $41.91 on Friday. The company’s 50-day moving average is $40.59. The company has a debt-to-equity ratio of 7.86, a quick ratio of 0.48 and a current ratio of 0.71. The stock has a market cap of $103.96 billion, a P/E ratio of 13.26, a PEG ratio of 2.12 and a beta of 0.74. GlaxoSmithKline plc has a 52-week low of $36.41 and a 52-week high of $42.20.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.14. The firm had revenue of $10.04 billion for the quarter, compared to the consensus estimate of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. As a group, equities research analysts forecast that GlaxoSmithKline plc will post 2.9 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, July 11th. Stockholders of record on Friday, May 17th were issued a dividend of $0.4953 per share. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.73%. The ex-dividend date of this dividend was Thursday, May 16th. GlaxoSmithKline’s payout ratio is presently 58.86%.

GSK has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on shares of in a research note on Monday, June 17th. They set an “equal weight” rating and a GBX 215 ($2.81) price objective for the company. Cowen restated a “buy” rating on shares of Aptinyx in a research note on Monday, June 10th. Finally, Zacks Investment Research upgraded shares of Green Brick Partners from a “sell” rating to a “hold” rating in a research note on Thursday, April 25th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and three have given a buy rating to the stock. GlaxoSmithKline currently has a consensus rating of “Hold” and an average price target of $42.66.

In related news, Director Plc Glaxosmithkline purchased 333,333 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were purchased at an average price of $15.00 per share, with a total value of $4,999,995.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 10.00% of the company’s stock.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding GSK?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GlaxoSmithKline and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts